Discovering The Potential of IGHV3-16 as A Drug Target Or Biomarker

Target Name: IGHV3-16

NCBI ID: G28447

IGHV3-16

Other Name(s): IGHV316 | immunoglobulin heavy variable 3-16 (non-functional) | VH | Immunoglobulin heavy variable 3-16 (non-functional)

Discovering The Potential of IGHV3-16 as A Drug Target Or Biomarker

IGHV3-16 (IGHV316) is a human interleukin-gene (IL-gene) that is expressed in various tissues and cells of the body. It is a member of the interleukin family, which includes cytokines, chemokines, and other signaling molecules that play crucial roles in the immune system. IGHV3-16 has been identified as a potential drug target or biomarker for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The IGHV3-16 gene is located on chromosome 14q34 and encodes a protein known as interleukin-gene (IL-gene) 3. IL-gene 3 is a cytokine that is involved in the regulation of immune responses, cell signaling, and inflammation. It is a key player in the interleukin family, which includes a variety of cytokines, chemokines, and other signaling molecules that are involved in the immune system.

IGHV3-16 has been shown to play a role in the development and progression of several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, studies have shown that high levels of IGHV3-16 are associated with an increased risk of cancer , including breast, ovarian, and lung cancer. Additionally, IGHV3-16 has been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis.

In addition to its potential role in disease, IGHV3-16 has also been identified as a potential drug target or biomarker. Studies have shown that IGHV3-16 can be targeted by small molecules, such as those used in drug development, and that this targeting can lead to the inhibition of its functions as an immune regulator. This suggests that IGHV3-16 may be a promising target for the development of new treatments for cancer, autoimmune disorders, and other diseases.

While more research is needed to fully understand the role of IGHV3-16 in disease and its potential as a drug target, studies have shown that it is a promising molecule for the development of new treatments for a variety of diseases. As research continues to advance , IGHV3-16 is likely to emerge as a key player in the field of immunology and the development of new treatments for disease.

Protein Name: Immunoglobulin Heavy Variable 3-16 (non-functional)

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of immunoglobulin heavy chains (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive immunoglobulin chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets